Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 8/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2971949 | 0.97 | P2RX3 (0.38) | CNR2P2RX3CNR1HDAC1HDAC6 | |
| SCHEMBL2977910 | 0.89 | HDAC6 (0.47) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL2981505 | 0.85 | CREBBP (0.37) | CNR2P2RX3CNR1HDAC1HDAC6 | |
| SCHEMBL2975842 | 0.85 | HDAC6 (0.50) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL2968792 | 0.82 | POLB (0.48) | CNR1 | |
| SCHEMBL2972874 | 0.81 | HDAC6 (0.52) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL2980297 | 0.80 | HDAC6 (0.51) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL2972921 | 0.79 | HDAC6 (0.42) | P2RX3HDAC1HDAC6 | |
| SCHEMBL2979418 | 0.78 | KDM4E (0.43) | HDAC1HDAC6HDAC3HDAC2HDAC10 | |
| SCHEMBL2979875 | 0.74 | HDAC6 (0.53) | HDAC1HDAC6HDAC3HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772245-B2 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20060199829-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199829-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | CNR2 3527/4885P2RX3 4817/4885HTR2A 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.